Lifeward Ltd. announced on September 9, 2025, that it has received its first payment from a commercial Medicare Advantage plan for a ReWalk 7 Personal Exoskeleton. This marks a significant step in expanding reimbursement coverage for the company's advanced mobility device.
The claim was processed in less than thirty days, indicating an accelerated timeline for payment. This progress, alongside additional improvements in traditional Medicare claim approvals, is expected to enhance the predictability and speed of revenue recognition for Lifeward.
This development builds on the established Medicare reimbursement pathway and the recent U.S. launch of the ReWalk 7. Expanding access through commercial Medicare Advantage plans is crucial for reaching a broader segment of the eligible patient population and driving market penetration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.